Stempoint Capital
Latest statistics and disclosures from Stempoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SNDX, ROIV, IMVT, MRUS, ARQT, and represent 38.78% of Stempoint Capital's stock portfolio.
- Added to shares of these 10 stocks: BMY (+$14M), SNDX (+$11M), INCY (+$8.6M), PRAX (+$8.3M), DAWN (+$7.1M), MRUS (+$6.6M), SLRN (+$6.5M), SLNO (+$6.2M), ARQT (+$5.2M), KROS (+$5.0M).
- Started 21 new stock positions in CNTA, RYTM, SLNO, BBIO, KROS, DAWN, CYTK, ATXS, TRML, INCY. URGN, SLRN, TERN, RVMD, SRPT, WVE, CAPR, ALKS, Mbx Biosciences, ZURA, BMY.
- Reduced shares in these 10 stocks: ACLX (-$18M), CRNX (-$17M), IMCR (-$12M), , GSK (-$9.5M), KALV (-$8.7M), EWTX (-$6.7M), INSM (-$5.8M), CLDX (-$5.3M), LRMR (-$5.1M).
- Sold out of its positions in SYRE, BDTX, CLDX, CRBP, FULC, GSK, IMCR, INSM, JSPR, KALV. LRMR, MRK, SLN.
- Stempoint Capital was a net seller of stock by $-23M.
- Stempoint Capital has $347M in assets under management (AUM), dropping by 4.81%.
- Central Index Key (CIK): 0001952142
Tip: Access up to 7 years of quarterly data
Positions held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stempoint Capital
Stempoint Capital holds 50 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals (SNDX) | 10.9 | $38M | +38% | 2.0M | 19.25 |
|
| Roivant Sciences SHS (ROIV) | 9.2 | $32M | +2% | 2.8M | 11.54 |
|
| Immunovant (IMVT) | 7.2 | $25M | -13% | 871k | 28.51 |
|
| Merus N V (MRUS) | 6.1 | $21M | +45% | 421k | 49.96 |
|
| Arcutis Biotherapeutics (ARQT) | 5.4 | $19M | +38% | 2.0M | 9.30 |
|
| Amicus Therapeutics (FOLD) | 4.6 | $16M | 1.5M | 10.68 |
|
|
| Applied Therapeutics (APLT) | 4.4 | $15M | -18% | 1.8M | 8.50 |
|
| Bristol Myers Squibb (BMY) | 4.1 | $14M | NEW | 275k | 51.74 |
|
| Crinetics Pharmaceuticals In (CRNX) | 3.2 | $11M | -61% | 214k | 51.10 |
|
| Biohaven (BHVN) | 3.1 | $11M | -7% | 216k | 49.97 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.9 | $10M | +494% | 174k | 57.54 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 2.7 | $9.5M | 2.6M | 3.63 |
|
|
| Incyte Corporation (INCY) | 2.5 | $8.6M | NEW | 130k | 66.10 |
|
| Denali Therapeutics (DNLI) | 2.4 | $8.2M | +12% | 282k | 29.13 |
|
| Day One Biopharmaceuticals I (DAWN) | 2.0 | $7.1M | NEW | 507k | 13.93 |
|
| Acelyrin (SLRN) | 1.9 | $6.5M | NEW | 1.3M | 4.93 |
|
| Soleno Therapeutics (SLNO) | 1.8 | $6.2M | NEW | 123k | 50.49 |
|
| Cabaletta Bio (CABA) | 1.7 | $6.0M | +8% | 1.3M | 4.72 |
|
| Immatics SHS (IMTX) | 1.5 | $5.1M | -10% | 450k | 11.41 |
|
| Keros Therapeutics (KROS) | 1.5 | $5.0M | NEW | 87k | 58.07 |
|
| Arcellx Common Stock (ACLX) | 1.4 | $5.0M | -78% | 60k | 83.51 |
|
| Nurix Therapeutics (NRIX) | 1.3 | $4.6M | 203k | 22.47 |
|
|
| Tscan Therapeutics (TCRX) | 1.2 | $4.3M | 861k | 4.98 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 1.2 | $4.2M | NEW | 1.0M | 4.06 |
|
| Ideaya Biosciences (IDYA) | 1.2 | $4.2M | +30% | 133k | 31.68 |
|
| Terns Pharmaceuticals (TERN) | 1.1 | $3.7M | NEW | 449k | 8.34 |
|
| Vistagen Therapeutics Ord (VTGN) | 1.0 | $3.6M | 1.8M | 1.94 |
|
|
| Perspective Therapeutics Com New (CATX) | 0.9 | $3.2M | -30% | 238k | 13.35 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.9 | $3.1M | -29% | 850k | 3.67 |
|
| Neurogene (NGNE) | 0.9 | $3.1M | -6% | 73k | 41.96 |
|
| Urogen Pharma (URGN) | 0.9 | $3.1M | NEW | 242k | 12.70 |
|
| Vigil Neuroscience (VIGL) | 0.7 | $2.5M | 744k | 3.40 |
|
|
| Wave Life Sciences SHS (WVE) | 0.7 | $2.5M | NEW | 300k | 8.20 |
|
| Bridgebio Pharma (BBIO) | 0.7 | $2.4M | NEW | 95k | 25.46 |
|
| Janux Therapeutics (JANX) | 0.6 | $2.2M | -46% | 49k | 45.43 |
|
| Surrozen Com New (SRZN) | 0.6 | $2.2M | +27% | 183k | 11.98 |
|
| Rhythm Pharmaceuticals (RYTM) | 0.6 | $2.2M | NEW | 41k | 52.39 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.6 | $2.1M | 200k | 10.45 |
|
|
| Sarepta Therapeutics (SRPT) | 0.5 | $1.9M | NEW | 15k | 124.89 |
|
| Protara Therapeutics Com Stk (TARA) | 0.5 | $1.7M | -4% | 943k | 1.83 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.4 | $1.5M | 150k | 10.02 |
|
|
| Tourmaline Bio (TRML) | 0.4 | $1.4M | NEW | 56k | 25.71 |
|
| Capricor Therapeutics Com New (CAPR) | 0.4 | $1.4M | NEW | 94k | 15.21 |
|
| Alkermes SHS (ALKS) | 0.4 | $1.4M | NEW | 49k | 27.99 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.4 | $1.3M | NEW | 84k | 15.99 |
|
| Mbx Biosciences | 0.4 | $1.3M | NEW | 50k | 25.98 |
|
| Cytokinetics Com New (CYTK) | 0.2 | $764k | NEW | 15k | 52.80 |
|
| Revolution Medicines (RVMD) | 0.2 | $755k | NEW | 17k | 45.35 |
|
| Astria Therapeutics (ATXS) | 0.2 | $619k | NEW | 56k | 10.99 |
|
| Edgewise Therapeutics (EWTX) | 0.2 | $531k | -92% | 20k | 26.69 |
|
Past Filings by Stempoint Capital
SEC 13F filings are viewable for Stempoint Capital going back to 2024
- Stempoint Capital 2024 Q3 filed Nov. 13, 2024
- Stempoint Capital 2024 Q2 restated filed Aug. 13, 2024
- Stempoint Capital 2024 Q1 restated filed Aug. 9, 2024